Fluorescence In Situ Hybridization (FISH)
This test detects rearrangements involving the ROS1 gene region (6q22) via fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded tissue specimens. FISH is performed using break-apart probes (Abbott Molecular) to qualitatively assess for the presence of ROS1 translocations that occur in non-small cell lung cancer. Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is positive for ROS1 rearrangement may respond to crizotinib therapy.
Interpretive report provided.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
This test will detect rearrangements involving ROS1, however it will not identify the translocation partner.
3 - 10 days
- Crizotinib evaluation for Non-small cell lung cancer (NSCLC)
A formalin-fixed, paraffin-embedded tissue block containing sufficient neoplastic cells is preferred. Unstained slides (3, 4-micron slides) with associated H&E stained slide are also acceptable. Decalcified tissue or other fixatives will be accepted and the assay attempted, however these may result in failed testing due to degraded nucleic acid. Both blocks and slides should be stored at room temperature.
By ordering this test the clinician acknowledges that informed consent has been obtained from the patient as required by applicable state or federal laws and the ordering clinician has authorization from the patient permitting MLabs to report the test results to the ordering clinician. Test includes pathologist interpretation of results billed as a separate additional charge. This test is not available without interpretation.